Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593393 | SCV000707322 | likely pathogenic | not provided | 2017-03-27 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003962710 | SCV004795936 | likely pathogenic | AKR1D1-related condition | 2023-12-27 | criteria provided, single submitter | clinical testing | The AKR1D1 c.580-1G>A variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0026% of alleles in individuals of European (Non-Finnish) descent in gnomAD. An alternative splice variant predicted to impact the same splice site, described as c.580-13T>A, has been reported in a patient affected with an inborn error of bile acid synthesis (Chen et al. 2020. PubMed ID: 31337596). Variants that disrupt the consensus splice acceptor site in AKR1D1 are expected to be pathogenic. In summary, the c.580-1G>A variant is interpreted as likely pathogenic. |